Mika Biologics: Microbial Systems. Immune Innovation. Beyond the Cell.

At Mika Biologics, we believe that the next era of biologics will be defined by precision, not scale — by the mastery of microbial systems rather than the pursuit of universal platforms. Our vision has always been to refine, not generalize. Nowhere is that philosophy embodied more clearly than in our state-of-the-art facility in Montreal, Canada — a hub purpose-built for microbial expression, immune biologics, and cell-free synthesis technologies.

The Montreal site represents the culmination of years of experience in biologics process design, bioreactor engineering, and translational manufacturing. It is equipped with cutting-edge fermentation suites, automated downstream purification systems, and modular cleanroom environments that support both R&D-scale and GMP-ready production. Designed with scalability and reproducibility in mind, the facility bridges the gap between bench-scale innovation and clinical-grade manufacturing, allowing our partners to move seamlessly from discovery to deployment.

Beyond its physical capabilities, our Montreal operation embodies the rigor and adaptability that modern biomanufacturing demands. Built to align with both Canadian and European regulatory frameworks, the site offers a flexible foundation for global biologics development. With integrated analytics, high-throughput screening, and real-time process monitoring, it empowers our teams — and our partners — to make data-driven decisions with speed and confidence.

This facility is more than a manufacturing site; it is a living demonstration of Mika’s microbial-first philosophy. Here, microbes are not mere production tools — they are the engines of innovation. Every aspect of the Montreal center, from strain engineering to process automation, is designed to unlock the biological potential of microbial systems and translate that power into tangible therapeutic and industrial breakthroughs.

Through our Montreal facility, Mika Biologics sets a new standard for precision-driven CDMO partnerships — one grounded in focus, sophistication, and scientific intent. It is a place where elegant biology meets advanced engineering, and where the future of microbial biologics is being built today.

Our Philosophy

The CDMO industry is often divided between catch-all providers that offer everything under one roof, and ultra-niche players that concentrate on a single modality. Mika Biologics takes a different path. We exist at the intersection of focus and breadth—providing multiple complementary services, but all tied together by one unifying theme: the microbial cell factory.

We see microbes not just as hosts, but as biological engines. Whether it’s E. coli, Pichia pastoris, or filamentous fungi, these organisms can be optimized to express immune cytokines, manufacture ribosome-rich extracts, secrete specialty enzymes, or even serve as vaccine scaffolds. By mastering microbial and cell-free systems, we accelerate biologics development in ways mammalian-focused CDMOs cannot—faster, more scalable, and often more sustainable.

At Mika, our goal is not to be everything to everyone. Our goal is to be indispensable to those developing the next generation of biologics.

What We Do Best

Mika Biologics is a contract development and manufacturing organization (CDMO) that specializes in microbial platforms. Our services are designed to meet clients wherever they are in their journey—from early-stage R&D to GMP production. What makes us different is the niche focus of our service portfolio, which spans:

• Cell-Free Biologics (TX–TL Systems): Extract-based transcription–translation systems that allow for on-demand protein synthesis, vaccine prototyping, and enzyme discovery without living cells.
• Immune Biologics (Cytokines & Immunomodulators): Manufacturing cytokines such as IL-2, IL-7, and GM-CSF in microbial hosts, with expertise in solubility, folding, and activity retention.
• Fungal & Yeast Expression Systems: Harnessing Pichia, Saccharomyces, and Aspergillus for secreted proteins, glycosylated enzymes, and specialty metabolites.
• Rare Biologics & Orphan-Scale GMP: Small-batch manufacturing for rare diseases and niche biologics often underserved by mainstream CDMOs.
• Synthetic Biology Tools & Enzyme Engineering: CRISPR proteins, polymerases, ligases, and other molecular biology workhorses made efficiently in microbial systems.
• Microbial Vaccines & VLPs (Virus-Like Particles): Fermentation-based vaccine scaffolds and engineered VLPs for immunization and nanomaterials.
• Endotoxin-Free Biologics: Leveraging engineered microbial strains (e.g., ClearColi®) to produce biologics and plasmids without the downstream burden of endotoxin clearance.
• Engineered Probiotic Biologics: Developing therapeutic probiotic strains and live microbial biologics to support the microbiome revolution.
• Biologic Nanoparticles: Self-assembling protein and enzyme scaffolds produced in microbial hosts for drug delivery, biomaterials, and next-gen therapies.

This portfolio is not accidental. Each niche builds on our microbial foundation, creating synergies across expression platforms and giving clients a menu of services that fit their innovation path.

Why Mika Biologics?

1. Microbial First

While many CDMOs treat microbial expression as a side capability, it is our core identity. This gives us sharper expertise, faster problem-solving, and deeper process knowledge in E. coli, yeast, and fungi.

2. Niche Yet Scalable

By concentrating on high-demand, emerging biologics niches, Mika offers specialization without irrelevance. From cytokines to cell-free extracts, our services align with where the biotech industry is heading.

3. Technical Elegance

We believe in doing more with less. Our processes are designed to minimize complexity while maximizing reproducibility, making scale-up more predictable and cost-efficient.

4. Global Readiness

From small orphan programs to globally scaled vaccine supply, we provide regulatory, quality, and logistics support across North America, Europe, and Asia.

5. Agility for Innovators

Whether you’re a biotech startup or a global pharma, our microbial-first platform can adapt to your project—fast. We pride ourselves on being responsive, transparent, and partner-driven.

Our Facilities

Mika Biologics operates state-of-the-art microbial fermentation facilities designed for flexibility and control. We support scales ranging from laboratory-scale (1–10 L) through pilot and GMP-ready (100–2,000 L), with partnerships for commercial-scale production up to (100,000L).

• Fermentation: Stainless steel and single-use systems for bacterial, yeast, and fungal hosts.
• Downstream Processing: Homogenization, centrifugation, tangential flow filtration (TFF), chromatography, and lyophilization.
• Analytics: qPCR, HPLC/UHPLC, SDS-PAGE, spectrophotometry, ELISA, bioassays.
• Quality Systems: ISO-aligned, FDA-registered, and EU-compliant.
• Digital Backbone: eBatch records, process historians, and PAT integration.

Our facilities are designed not just to produce biologics, but to inspire confidence. We welcome client audits and provide full transparency in data, process, and quality.

Our Clients

Mika Biologics partners with:

• Biopharma companies developing immunotherapies, rare biologics, and vaccines.
• Synthetic biology startups engineering enzymes, cell-free systems, and biomaterials.
• Global health organizations seeking scalable microbial vaccine solutions.
• Alternative protein and sustainability ventures applying fungal and microbial hosts to food and industrial bio.

For each client, we act not as a vendor, but as a strategic partner—helping shape project strategy, reduce risk, and accelerate timelines.

Our Vision

We envision a world where microbial and cell-free systems become the backbone of biologics manufacturing.

• Faster therapies through cell-free synthesis.
• More affordable biologics through microbial efficiency.
• Sustainable production through fungal and yeast platforms.
• Smarter immunotherapies through cytokine and immune protein mastery.

Mika Biologics exists to help make that vision real. By focusing on microbial-first innovation, we give our clients the power to develop therapies that are not only effective, but accessible, scalable, and future-ready.

Closing Statement

In a crowded CDMO market, Mika Biologics chooses focus. We are not mammalian generalists. We are microbial specialists. By mastering cytokines, cell-free systems, fungal expression, and rare biologics, we create value where others see complexity.

We are Mika Biologics.

Microbial Systems. Immune Innovation. Beyond the Cell.

Have a question? Contact sales at info@mikabiologics.com